STERIS plc $STE Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. raised its stake in STERIS plc (NYSE:STE) by 11.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 53,645 shares of the medical equipment provider’s stock after buying an additional 5,553 shares during the period. PNC Financial Services Group Inc.’s holdings in STERIS were worth $13,274,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of STERIS in the third quarter valued at about $25,000. Geneos Wealth Management Inc. raised its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Spurstone Advisory Services LLC acquired a new position in STERIS in the 2nd quarter valued at about $29,000. Cloud Capital Management LLC purchased a new stake in shares of STERIS in the 3rd quarter valued at approximately $29,000. Finally, TruNorth Capital Management LLC purchased a new stake in shares of STERIS in the 3rd quarter valued at approximately $37,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

NYSE:STE opened at $249.87 on Thursday. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The company has a 50 day moving average price of $256.16 and a 200 day moving average price of $250.93. The stock has a market capitalization of $24.50 billion, a P/E ratio of 34.85 and a beta of 1.03.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same quarter in the previous year, the business earned $2.32 EPS. The firm’s revenue was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities research analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is 35.15%.

Analyst Ratings Changes

Several research firms have recently commented on STE. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.20.

Insiders Place Their Bets

In other STERIS news, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the transaction, the vice president directly owned 10,710 shares of the company’s stock, valued at $2,806,020. The trade was a 31.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.07% of the stock is currently owned by corporate insiders.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.